Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure (an update on the sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

Seferovic P. M., Fragasso G., Petrie M., Mullens W., Ferrari R., Thum T., ...Daha Fazla

EUROPEAN JOURNAL OF HEART FAILURE, cilt.22, sa.11, ss.1984-1986, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1002/ejhf.2026
  • Dergi Adı: EUROPEAN JOURNAL OF HEART FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1984-1986
  • Anahtar Kelimeler: Heart failure, Sodium&#8211, glucose co&#8208, transporter 2 inhibitors, Type 2 diabetes mellitus, Cardiovascular outcomes, Renal function
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: